{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T16:06:07Z","timestamp":1786982767270,"version":"build-2736575974"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2018,12,11]],"date-time":"2018-12-11T00:00:00Z","timestamp":1544486400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs Aging"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1007\/s40266-018-0625-4","type":"journal-article","created":{"date-parts":[[2018,12,10]],"date-time":"2018-12-10T22:04:08Z","timestamp":1544479448000},"page":"137-146","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":16,"title":["Contemporary Management of Heart Failure in the Elderly"],"prefix":"10.1007","volume":"36","author":[{"given":"Joanna","family":"Osmanska","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pardeep S.","family":"Jhund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,12,11]]},"reference":[{"key":"625_CR1","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1016\/S0140-6736(17)32520-5","volume":"391","author":"N Conrad","year":"2018","unstructured":"Conrad N, Judge A, Tran J, Mohseni H, Hedgecott D, Crespillo AP, Allison M, Hemingway H, Cleland JG, McMurray JJV, Rahimi K. Temporal trends and patterns in heart failure incidence: a population-based study of 4\u00a0million individuals. Lancet. 2018;391:572\u201380.","journal-title":"Lancet"},{"key":"625_CR2","doi-asserted-by":"publisher","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","volume":"353","author":"A Hjalmarson","year":"1999","unstructured":"Hjalmarson A, Goldstein S, Fagerberg B, Wedel H, Waagstein F, Kjekshus J, Wikstrand J, Westergren G, Thimell M, El Allaf D, V\u00edtovec J, Aldershvile J, Halinen M, Dietz R, Neuhaus KL, J\u00e1nosi A, Thorgeirsson G, Dunselman P, Gullestad L, Kuch J, Herlitz J, Rickenbacher P, Ball S, Gottlieb S, Deedwania P, Vandenhoven G, Nov\u00e1kov\u00e1 I, Danker S, Lundstr\u00f6m M, Meyer-Sabellek W, et al. Effect of metoprolol CR\/XL in chronic heart failure: metoprolol CR\/XL randomised intervention trial in congestive heart failure (MERIT-HF). Lancet. 1999;353:2001\u20137.","journal-title":"Lancet"},{"key":"625_CR3","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN, SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med."},{"key":"625_CR4","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1093\/eurjhf\/hfr116","volume":"13","author":"UM Mogensen","year":"2011","unstructured":"Mogensen UM, Ersb\u00f8ll M, Andersen M, Andersson C, Hassager C, Torp-Pedersen C, Gustafsson F, K\u00f8ber L. Clinical characteristics and major comorbidities in heart failure patients more than 85\u00a0years of age compared with younger age groups. Eur J Heart Fail. 2011;13:1216\u201323.","journal-title":"Eur J Heart Fail"},{"key":"625_CR5","doi-asserted-by":"publisher","first-page":"2714","DOI":"10.1093\/eurheartj\/ehu216","volume":"35","author":"CM Wong","year":"2014","unstructured":"Wong CM, Hawkins NM, Petrie MC, Jhund PS, Gardner RS, Ariti CA, Poppe KK, Earle N, Whalley GA, Squire IB, Doughty RN, McMurray JJV, Berry C, Doughty R, Granger C, Kober L, Massie B, McAlister F, McMurray J, Pocock S, Poppe K, Swedberg K, Somaratne J, Whalley G, Ahmed A, Andersson B, Bayes-Genis A, Berry C, Cowie M, Cubbon R, et al. Heart failure in younger patients: the meta-analysis global group in chronic heart failure (MAGGIC). Eur Heart J. 2014;35:2714\u201321.","journal-title":"Eur Heart J"},{"key":"625_CR6","doi-asserted-by":"publisher","first-page":"1735","DOI":"10.1056\/NEJM199212103272408","volume":"327","author":"JY Wei","year":"1992","unstructured":"Wei JY. Age and the cardiovascular system. N Engl J Med. 1992;327:1735\u20139.","journal-title":"N Engl J Med"},{"key":"625_CR7","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1002\/ejhf.592","volume":"18","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonz\u00e1lez-Juanatey JR, Harjola V-P, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P, Authors\/Task Force Members, Document Reviewers. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure: the Task Force for the diagnosis and treatment of acute and chronic heart failure of the European Society of Cardiology (ESC). Developed with the special contribution of the Heart Failure Association of the ESC. Eur J Heart Fail. 2016;18:891\u2013975.","journal-title":"Eur J Heart Fail."},{"key":"625_CR8","doi-asserted-by":"publisher","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"P Ponikowski","year":"2016","unstructured":"Ponikowski P, Voors AA, Anker SD, Bueno H, Cleland JGF, Coats AJS, Falk V, Gonzalez-Juanatey JR, Harjola VP, Jankowska EA, Jessup M, Linde C, Nihoyannopoulos P, Parissis JT, Pieske B, Riley JP, Rosano GMC, Ruilope LM, Ruschitzka F, Rutten FH, van der Meer P. 2016 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2016;37:2129\u2013200.","journal-title":"Eur Heart J"},{"key":"625_CR9","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.1161\/CIR.0000000000000509","volume":"136","author":"CW Yancy","year":"2017","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Colvin MM, Drazner MH, Filippatos GS, Fonarow GC, Givertz MM, Hollenberg SM, Lindenfeld J, Masoudi FA, McBride PE, Peterson PN, Stevenson LW, Westlake C. 2017 ACC\/AHA\/HFSA focused update of the 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology\/American Heart Association Task Force on clinical practice guidelines and the Heart Failure Society of America. Circulation. 2017;136:e137\u201361.","journal-title":"Circulation"},{"key":"625_CR10","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429\u201335.","journal-title":"N Engl J Med"},{"key":"625_CR11","doi-asserted-by":"publisher","first-page":"1450","DOI":"10.1001\/jama.1995.03520420066040","volume":"273","author":"R Garg","year":"1995","unstructured":"Garg R, Yusuf S, Collaborative Group on ACE Inhibitor Trials. Overview of randomized trials of angiotensin-converting enzyme inhibitors on mortality and morbidity in patients with heart failure. JAMA. 1995;273:1450\u20136.","journal-title":"JAMA."},{"key":"625_CR12","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","volume":"362","author":"CB Granger","year":"2003","unstructured":"Granger CB, McMurray JJV, Yusuf S, Held P, Michelson EL, Olofsson B, Ostergren J, Pfeffer MA, Swedberg K, CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: the CHARM-Alternative trial. Lancet. 2003;362:772\u20136.","journal-title":"Lancet."},{"key":"625_CR13","doi-asserted-by":"publisher","first-page":"3022","DOI":"10.1093\/eurheartj\/ehn476","volume":"29","author":"A Cohen-Solal","year":"2008","unstructured":"Cohen-Solal A, McMurray JJ, Swedberg K, Pfeffer MA, Puu M, Solomon SD, Michelson EL, Yusuf S, Granger CB, CHARM Investigators. Benefits and safety of candesartan treatment in heart failure are independent of age: insights from the Candesartan in Heart failure-Assessment of Reduction in Mortality and morbidity programme. Eur Heart J. 2008;29:3022\u20138.","journal-title":"Eur Heart J."},{"key":"625_CR14","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1093\/eurheartj\/ehi115","volume":"26","author":"MD Flather","year":"2005","unstructured":"Flather MD, Shibata MC, Coats AJS, van Veldhuisen DJ, Parkhomenko A, Borbola J, Cohen-Solal A, Dumitrascu D, Ferrari R, Lechat P, Soler-Soler J, Tavazzi L, Spinarova L, Toman J, B\u00f6hm M, Anker SD, Thompson SG, Poole-Wilson PA, SENIORS Investigators. Randomized trial to determine the effect of nebivolol on mortality and cardiovascular hospital admission in elderly patients with heart failure (SENIORS). Eur Heart J. 2005;26:215\u201325.","journal-title":"Eur Heart J."},{"key":"625_CR15","doi-asserted-by":"publisher","first-page":"2150","DOI":"10.1016\/j.jacc.2009.02.046","volume":"53","author":"DJ Veldhuisen van","year":"2009","unstructured":"van Veldhuisen DJ, Cohen-Solal A, B\u00f6hm M, Anker SD, Babalis D, Roughton M, Coats AJS, Poole-Wilson PA, Flather MD, SENIORS Investigators. Beta-blockade with nebivolol in elderly heart failure patients with impaired and preserved left ventricular ejection fraction: data from SENIORS (Study of Effects of Nebivolol Intervention on Outcomes and Rehospitalization in Seniors With Heart Failure). J Am Coll Cardiol. 2009;53:2150\u20138.","journal-title":"J Am Coll Cardiol."},{"key":"625_CR16","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1093\/eurjhf\/hfr020","volume":"13","author":"H-D D\u00fcngen","year":"2011","unstructured":"D\u00fcngen H-D, Apostolovi\u0107 S, Inkrot S, Tahirovi\u0107 E, T\u00f6pper A, Mehrhof F, Prettin C, Putnikovi\u0107 B, Ne\u0161kovi\u0107 AN, Krotin M, Saka\u010d D, Lain\u0161\u010dak M, Edelmann F, Wachter R, Rau T, Eschenhagen T, Doehner W, Anker SD, Waagstein F, Herrmann-Lingen C, Gelbrich G, Dietz R. Titration to target dose of bisoprolol vs. carvedilol in elderly patients with heart failure: the CIBIS-ELD trial. Eur J Heart Fail. 2011;13:670\u201380.","journal-title":"Eur J Heart Fail."},{"key":"625_CR17","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J, Randomized Aldactone Evaluation Study Investigators. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med."},{"key":"625_CR18","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1009492","volume":"364","author":"F Zannad","year":"2011","unstructured":"Zannad F, McMurray JJV, Krum H, van Veldhuisen DJ, Swedberg K, Shi H, Vincent J, Pocock SJ, Pitt B. Eplerenone in patients with systolic heart failure and mild symptoms. N Engl J Med. 2011;364:11\u201321.","journal-title":"N Engl J Med"},{"key":"625_CR19","doi-asserted-by":"publisher","first-page":"993","DOI":"10.1056\/NEJMoa1409077","volume":"371","author":"JJV McMurray","year":"2014","unstructured":"McMurray JJV, Packer M, Desai AS, Gong J, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med. 2014;371:993\u20131004.","journal-title":"N Engl J Med."},{"key":"625_CR20","doi-asserted-by":"publisher","first-page":"2576","DOI":"10.1093\/eurheartj\/ehv330","volume":"36","author":"PS Jhund","year":"2015","unstructured":"Jhund PS, Fu M, Bayram E, Chen C-H, Negrusz-Kawecka M, Rosenthal A, Desai AS, Lefkowitz MP, Rizkala AR, Rouleau JL, Shi VC, Solomon SD, Swedberg K, Zile MR, McMurray JJV, Packer M, PARADIGM-HF Investigators and Committees. Efficacy and safety of LCZ696 (sacubitril-valsartan) according to age: insights from PARADIGM-HF. Eur Heart J. 2015;36:2576\u201384.","journal-title":"Eur Heart J."},{"key":"625_CR21","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1002\/ejhf.687","volume":"19","author":"JA Cannon","year":"2017","unstructured":"Cannon JA, Shen L, Jhund PS, Kristensen SL, K\u00f8ber L, Chen F, Gong J, Lefkowitz MP, Rouleau JL, Shi VC, Swedberg K, Zile MR, Solomon SD, Packer M, McMurray JJV. Dementia-related adverse events in PARADIGM-HF and other trials in heart failure with reduced ejection fraction. Eur J Heart Fail. 2017;19:129\u201337.","journal-title":"Eur J Heart Fail"},{"key":"625_CR22","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","volume":"376","author":"K Swedberg","year":"2010","unstructured":"Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Ford I, Dubost-Brama A, Lerebours G, Tavazzi L. Ivabradine and outcomes in chronic heart failure (SHIFT): a randomised placebo-controlled study. Lancet. 2010;376:875\u201385.","journal-title":"Lancet"},{"key":"625_CR23","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.1093\/eurjhf\/hft102","volume":"15","author":"L Tavazzi","year":"2013","unstructured":"Tavazzi L, Swedberg K, Komajda M, B\u00f6hm M, Borer JS, Lainscak M, Ford I. Efficacy and safety of ivabradine in chronic heart failure across the age spectrum: insights from the SHIFT study. Eur J Heart Fail. 2013;15:1296\u2013303.","journal-title":"Eur J Heart Fail"},{"key":"625_CR24","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1056\/NEJM199702203360801","volume":"336","author":"Digitalis Investigation Group","year":"1997","unstructured":"Digitalis Investigation Group. The effect of digoxin on mortality and morbidity in patients with heart failure. N Engl J Med. 1997;336:525\u201333.","journal-title":"N Engl J Med"},{"key":"625_CR25","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1016\/S0735-1097(01)01442-5","volume":"38","author":"MW Rich","year":"2001","unstructured":"Rich MW, McSherry F, Williford WO, Yusuf S. Effect of age on mortality, hospitalizations and response to digoxin in patients with heart failure: the DIG study. J Am Coll Cardiol. 2001;38:806\u201313.","journal-title":"J Am Coll Cardiol"},{"key":"625_CR26","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1056\/NEJM198606123142404","volume":"314","author":"JN Cohn","year":"1986","unstructured":"Cohn JN, Archibald DG, Ziesche S, Franciosa JA, Harston WE, Tristani FE, Dunkman WB, Jacobs W, Francis GS, Flohr KH. Effect of vasodilator therapy on mortality in chronic congestive heart failure: results of a Veterans Administration Cooperative Study. N Engl J Med. 1986;314:1547\u201352.","journal-title":"N Engl J Med"},{"key":"625_CR27","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1056\/NEJM199108013250502","volume":"325","author":"JN Cohn","year":"1991","unstructured":"Cohn JN, Johnson G, Ziesche S, Cobb F, Francis G, Tristani F, Smith R, Dunkman WB, Loeb H, Wong M. A comparison of enalapril with hydralazine-isosorbide dinitrate in the treatment of chronic congestive heart failure. N Engl J Med. 1991;325:303\u201310.","journal-title":"N Engl J Med"},{"key":"625_CR28","doi-asserted-by":"publisher","first-page":"2049","DOI":"10.1056\/NEJMoa042934","volume":"351","author":"AL Taylor","year":"2004","unstructured":"Taylor AL, Ziesche S, Yancy C, Carson P, D\u2019Agostino R, Ferdinand K, Taylor M, Adams K, Sabolinski M, Worcel M, Cohn JN, African-American Heart Failure Trial Investigators. Combination of isosorbide dinitrate and hydralazine in blacks with heart failure. N Engl J Med. 2004;351:2049\u201357.","journal-title":"N Engl J Med."},{"key":"625_CR29","doi-asserted-by":"publisher","first-page":"592","DOI":"10.7326\/0003-4819-153-9-201011020-00009","volume":"153","author":"P Santangeli","year":"2010","unstructured":"Santangeli P, Di Biase L, Dello Russo A, Casella M, Bartoletti S, Santarelli P, Pelargonio G, Natale A. Meta-analysis: age and effectiveness of prophylactic implantable cardioverter-defibrillators. Ann Intern Med. 2010;153:592\u20139.","journal-title":"Ann Intern Med"},{"key":"625_CR30","doi-asserted-by":"publisher","first-page":"503","DOI":"10.5603\/CJ.2011.0005","volume":"18","author":"MH Kong","year":"2011","unstructured":"Kong MH, Al-Khatib SM, Sanders GD, Hasselblad V, Peterson ED. Use of implantable cardioverter-defibrillators for primary prevention in older patients: a systematic literature review and meta-analysis. Cardiol J. 2011;18:503\u201314.","journal-title":"Cardiol J."},{"key":"625_CR31","doi-asserted-by":"publisher","first-page":"111","DOI":"10.7326\/M13-1787","volume":"160","author":"A Earley","year":"2014","unstructured":"Earley A, Persson R, Garlitski AC, Balk EM, Uhlig K. Effectiveness of implantable cardioverter defibrillators for primary prevention of sudden cardiac death in subgroups a systematic review. Ann Intern Med. 2014;160:111\u201321.","journal-title":"Ann Intern Med"},{"key":"625_CR32","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1093\/europace\/euu296","volume":"17","author":"S Barra","year":"2015","unstructured":"Barra S, Provid\u00eancia R, Paiva L, Heck P, Agarwal S. Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. Europace. 2015;17:174\u201386.","journal-title":"Europace."},{"key":"625_CR33","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1136\/heartjnl-2016-310850","volume":"104","author":"SAS Beggs","year":"2018","unstructured":"Beggs SAS, Jhund PS, Jackson CE, McMurray JJV, Gardner RS. Non-ischaemic cardiomyopathy, sudden death and implantable defibrillators: a review and meta-analysis. Heart. 2018;104:144\u201350.","journal-title":"Heart"},{"key":"625_CR34","doi-asserted-by":"publisher","first-page":"1772","DOI":"10.1161\/CIRCULATIONAHA.117.028829","volume":"136","author":"MB Elming","year":"2017","unstructured":"Elming MB, Nielsen JC, Haarbo J, Videb\u00e6k L, Korup E, Signorovitch J, Olesen LL, Hildebrandt P, Steffensen FH, Bruun NE, Eiskj\u00e6r H, Brandes A, Th\u00f8gersen AM, Gustafsson F, Egstrup K, Videb\u00e6k R, Hassager C, Svendsen JH, H\u00f8fsten DE, Torp-Pedersen C, Pehrson S, K\u00f8ber L, Thune JJ. Age and outcomes of primary prevention implantable cardioverter-defibrillators in patients with nonischemic systolic heart failure. Circulation. 2017;136:1772\u201380.","journal-title":"Circulation"},{"key":"625_CR35","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1161\/CIRCOUTCOMES.114.001306","volume":"8","author":"PL Hess","year":"2015","unstructured":"Hess PL, Al-Khatib SM, Han JY, Edwards R, Bardy GH, Bigger JT, Buxton A, Cappato R, Dorian P, Hallstrom A, Kadish AH, Kudenchuk PJ, Lee KL, Mark DB, Moss AJ, Steinman R, Inoue LYT, Sanders G. Survival benefit of the primary prevention implantable cardioverter-defibrillator among older patients: does age matter? An analysis of pooled data from 5 clinical trials. Circ Cardiovasc Qual Outcomes. 2015;8:179\u201386.","journal-title":"Circ Cardiovasc Qual Outcomes."},{"key":"625_CR36","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1016\/j.cardfail.2015.09.015","volume":"22","author":"S Thomas","year":"2016","unstructured":"Thomas S, Moss AJ, Zareba W, McNitt S, Barsheshet A, Klein H, Goldenberg I, Huang DT, Biton Y, Kutyifa V. Cardiac resynchronization in different age groups: a MADIT-CRT long-term follow-up substudy. J Card Fail. 2016;22:143\u20139.","journal-title":"J Card Fail."},{"key":"625_CR37","doi-asserted-by":"publisher","first-page":"3547","DOI":"10.1093\/eurheartj\/eht290","volume":"34","author":"JG Cleland","year":"2013","unstructured":"Cleland JG, Abraham WT, Linde C, Gold MR, Young JB, Claude Daubert J, Sherfesee L, Wells GA, Tang ASL. An individual patient meta-analysis of five randomized trials assessing the effects of cardiac resynchronization therapy on morbidity and mortality in patients with symptomatic heart failure. Eur Heart J. 2013;34:3547\u201356.","journal-title":"Eur Heart J"},{"key":"625_CR38","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1111\/j.1540-8167.2011.02011.x","volume":"22","author":"J Penn","year":"2011","unstructured":"Penn J, Goldenberg I, Moss AJ, McNitt S, Zareba W, Klein HU, Cannom DS, Solomon SD, Barsheshet A, Huang DT, MADIT-CRT Trial investigators. Improved outcome with preventive cardiac resynchronization therapy in the elderly: a MADIT-CRT substudy. J Cardiovasc Electrophysiol. 2011;22:892\u20137.","journal-title":"J Cardiovasc Electrophysiol."},{"key":"625_CR39","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1016\/j.ijcard.2016.11.212","volume":"228","author":"J K\u00f6be","year":"2017","unstructured":"K\u00f6be J, Andresen D, Maier S, Stellbrink C, Kleemann T, Gonska B-D, Reif S, Hochadel M, Senges J, Eckardt L. Complications and 1-year benefit of cardiac resynchronization therapy in patients over 75\u00a0years of age: insights from the German Device Registry. Int J Cardiol. 2017;228:784\u20139.","journal-title":"Int J Cardiol"},{"key":"625_CR40","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.1056\/NEJMoa1100356","volume":"364","author":"EJ Velazquez","year":"2011","unstructured":"Velazquez EJ, Lee KL, Deja MA, Jain A, Sopko G, Marchenko A, Ali IS, Pohost G, Gradinac S, Abraham WT, Yii M, Prabhakaran D, Szwed H, Ferrazzi P, Petrie MC, O\u2019Connor CM, Panchavinnin P, She L, Bonow RO, Rankin GR, Jones RH, Rouleau J-L. Coronary-artery bypass surgery in patients with left ventricular dysfunction. N Engl J Med. 2011;364:1607\u201316.","journal-title":"N Engl J Med"},{"key":"625_CR41","doi-asserted-by":"publisher","first-page":"1314","DOI":"10.1161\/CIRCULATIONAHA.116.024800","volume":"134","author":"MC Petrie","year":"2016","unstructured":"Petrie MC, Jhund PS, She L, Adlbrecht C, Doenst T, Panza JA, Hill JA, Lee KL, Rouleau JL, Prior DL, Ali IS, Maddury J, Golba KS, White HD, Carson P, Chrzanowski L, Romanov A, Miller AB, Velazquez EJ, STICH Trial Investigators. Ten-year outcomes after coronary artery bypass grafting according to age in patients with heart failure and left ventricular systolic dysfunction: an analysis of the extended follow-up of the STICH trial (Surgical Treatment for Ischemic Heart Failure). Circulation. 2016;134:1314\u201324.","journal-title":"Circulation."},{"key":"625_CR42","doi-asserted-by":"publisher","first-page":"2739","DOI":"10.1093\/eurheartj\/ehx391","volume":"38","author":"H Baumgartner","year":"2017","unstructured":"Baumgartner H, Falk V, Bax JJ, De Bonis M, Hamm C, Holm PJ, Iung B, Lancellotti P, Lansac E, Rodriguez Mu\u00f1oz D, Rosenhek R, Sj\u00f6gren J, Tornos Mas P, Vahanian A, Walther T, Wendler O, Windecker S, Zamorano JL, ESC Scientific Document Group. 2017 ESC\/EACTS guidelines for the management of valvular heart disease. Eur Heart J. 2017;38:2739\u201391.","journal-title":"Eur Heart J."},{"key":"625_CR43","doi-asserted-by":"publisher","DOI":"10.1056\/nejmoa1806640","author":"GW Stone","year":"2018","unstructured":"Stone GW, Lindenfeld J, Abraham WT, Kar S, Lim DS, Mishell JM, Whisenant B, Grayburn PA, Rinaldi M, Kapadia SR, Rajagopal V, Sarembock IJ, Brieke A, Marx SO, Cohen DJ, Weissman NJ, Mack MJ, COAPT Investigators. Transcatheter mitral-valve repair in patients with heart failure. N Engl J Med. 2018. \n                    https:\/\/doi.org\/10.1056\/nejmoa1806640\n                    \n                  \n                           (epub ahead of print).","journal-title":"N Engl J Med."},{"key":"625_CR44","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.athoracsur.2013.04.010","volume":"96","author":"P Atluri","year":"2013","unstructured":"Atluri P, Goldstone AB, Kobrin DM, Cohen JE, MacArthur JW, Howard JL, Jessup ML, Rame JE, Acker MA, Woo YJ. Ventricular assist device implant in the elderly is associated with increased, but respectable risk: a multi-institutional study. Ann Thorac Surg. 2013;96:141\u20137.","journal-title":"Ann Thorac Surg"},{"key":"625_CR45","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1016\/j.healun.2013.08.006","volume":"32","author":"LH Lund","year":"2013","unstructured":"Lund LH, Edwards LB, Kucheryavaya AY, Dipchand AI, Benden C, Christie JD, Dobbels F, Kirk R, Rahmel AO, Yusen RD, Stehlik J, International Society for Heart and Lung Transplantation. The Registry of the International Society for Heart and Lung Transplantation: Thirtieth Official Adult Heart Transplant Report: 2013; focus theme: age. J Heart Lung Transplant. 2013;32:951\u201364.","journal-title":"J Heart Lung Transplant."},{"key":"625_CR46","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1080\/14779072.2018.1417039","volume":"16","author":"N Nair","year":"2018","unstructured":"Nair N, Gongora E. Reviewing the use of ventricular assist devices in the elderly: where do we stand today? Expert Rev Cardiovasc Ther. 2018;16:11\u201320.","journal-title":"Expert Rev Cardiovasc Ther."},{"key":"625_CR47","doi-asserted-by":"publisher","first-page":"3135","DOI":"10.1093\/eurheartj\/ehw114","volume":"37","author":"AS Desai","year":"2016","unstructured":"Desai AS, Jhund PS. After TOPCAT: what to do now in heart failure with preserved ejection fraction. Eur Heart J. 2016;37:3135\u201340.","journal-title":"Eur Heart J"},{"key":"625_CR48","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.1093\/eurheartj\/ehl250","volume":"27","author":"JGF Cleland","year":"2006","unstructured":"Cleland JGF, Tendera M, Adamus J, Freemantle N, Polonski L, Taylor J. The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J. 2006;27:2338\u201345.","journal-title":"Eur Heart J"},{"key":"625_CR49","doi-asserted-by":"publisher","first-page":"777","DOI":"10.1016\/S0140-6736(03)14285-7","volume":"362","author":"S Yusuf","year":"2003","unstructured":"Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJV, Michelson EL, Olofsson B, Ostergren J. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved trial. Lancet. 2003;362:777\u201381.","journal-title":"Lancet"},{"key":"625_CR50","doi-asserted-by":"publisher","first-page":"2456","DOI":"10.1056\/NEJMoa0805450","volume":"359","author":"BM Massie","year":"2008","unstructured":"Massie BM, Carson PE, McMurray JJ, Komajda M, McKelvie R, Zile MR, Anderson S, Donovan M, Iverson E, Staiger C, Ptaszynska A. Irbesartan in patients with heart failure and preserved ejection fraction. N Engl J Med. 2008;359:2456\u201367.","journal-title":"N Engl J Med"},{"key":"625_CR51","doi-asserted-by":"publisher","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","volume":"370","author":"B Pitt","year":"2014","unstructured":"Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O\u2019Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM. Spironolactone for heart failure with preserved ejection fraction. N Engl J Med. 2014;370:1383\u201392.","journal-title":"N Engl J Med"},{"key":"625_CR52","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1002\/ejhf.876","volume":"19","author":"M Komajda","year":"2017","unstructured":"Komajda M, Isnard R, Cohen-Solal A, Metra M, Pieske B, Ponikowski P, Voors AA, Dominjon F, Henon-Goburdhun C, Pannaux M, B\u00f6hm M, prEserveD left ventricular ejectIon fraction chronic heart Failure with ivabradine studY (EDIFY) Investigators. Effect of ivabradine in patients with heart failure with preserved ejection fraction: the EDIFY randomized placebo-controlled trial. Eur J Heart Fail. 2017;19:1495\u2013503.","journal-title":"Eur J Heart Fail."},{"key":"625_CR53","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1016\/j.jchf.2017.04.013","volume":"5","author":"SD Solomon","year":"2017","unstructured":"Solomon SD, Rizkala AR, Gong J, Wang W, Anand IS, Ge J, Lam CSP, Maggioni AP, Martinez F, Packer M, Pfeffer MA, Pieske B, Redfield MM, Rouleau JL, van Veldhuisen DJ, Zannad F, Zile MR, Desai AS, Shi VC, Lefkowitz MP, McMurray JJV. Angiotensin receptor neprilysin inhibition in heart failure with preserved ejection fraction: rationale and design of the PARAGON-HF trial. JACC Heart Fail. 2017;5:471\u201382.","journal-title":"JACC Heart Fail."},{"key":"625_CR54","first-page":"e240","volume":"128","author":"CW Yancy","year":"2013","unstructured":"Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJV, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WHW, Tsai EJ, Wilkoff BL. 2013 ACCF\/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation\/American Heart Association Task Force on practice guidelines. Circulation. 2013;128:e240\u2013327.","journal-title":"Circulation"},{"key":"625_CR55","doi-asserted-by":"publisher","first-page":"293","DOI":"10.1056\/NEJM199108013250501","volume":"325","author":"S Yusuf","year":"1991","unstructured":"Yusuf S, Pitt B, Davis CE, Hood WB, Cohn JN, SOLVD Investigators. Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. N Engl J Med. 1991;325:293\u2013302.","journal-title":"N Engl J Med."},{"key":"625_CR56","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1056\/NEJM198706043162301","volume":"316","author":"CONSENSUS Trial Study Group","year":"1987","unstructured":"CONSENSUS Trial Study Group. Effects of enalapril on mortality in severe congestive heart failure: results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). N Engl J Med. 1987;316:1429\u201335.","journal-title":"N Engl J Med."},{"key":"625_CR57","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1016\/j.jacc.2008.04.069","volume":"52","author":"S Masson","year":"2008","unstructured":"Masson S, Latini R, Anand IS, Barlera S, Angelici L, Vago T, Tognoni G, Cohn JN. Prognostic value of changes in N-terminal pro-brain natriuretic peptide in Val-HeFT (Valsartan Heart Failure Trial). J Am Coll Cardiol. 2008;52:997\u20131003.","journal-title":"J Am Coll Cardiol"},{"key":"625_CR58","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","volume":"353","author":"CIBIS-II Investigators and Committees","year":"1999","unstructured":"CIBIS-II Investigators and Committees. The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): a randomised trial. Lancet. 1999;353:9\u201313.","journal-title":"Lancet"},{"key":"625_CR59","doi-asserted-by":"publisher","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","volume":"106","author":"M Packer","year":"2002","unstructured":"Packer M, Fowler MB, Roecker EB, Coats AJS, Katus HA, Krum H, Mohacsi P, Rouleau JL, Tendera M, Staiger C, Holcslaw TL, Amann-Zalan I, DeMets DL, Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) Study Group. Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the Carvedilol Prospective Randomized Cumulative Survival (COPERNICUS) study. Circulation. 2002;106:2194\u20139.","journal-title":"Circulation."},{"key":"625_CR60","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1056\/NEJM199909023411001","volume":"341","author":"B Pitt","year":"1999","unstructured":"Pitt B, Zannad F, Remme WJ, Cody R, Castaigne A, Perez A, Palensky J, Wittes J. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. N Engl J Med. 1999;341:709\u201317.","journal-title":"N Engl J Med"},{"key":"625_CR61","doi-asserted-by":"publisher","first-page":"1667","DOI":"10.1056\/NEJMoa010713","volume":"345","author":"JN Cohn","year":"2001","unstructured":"Cohn JN, Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 2001;345:1667\u201375.","journal-title":"N Engl J Med"},{"key":"625_CR62","doi-asserted-by":"publisher","first-page":"i1855","DOI":"10.1136\/bmj.i1855","volume":"353","author":"D Kotecha","year":"2016","unstructured":"Kotecha D, Manzano L, Krum H, Rosano G, Holmes J, Altman DG, Collins PD, Packer M, Wikstrand J, Coats AJS, Cleland JGF, Kirchhof P, von Lueder TG, Rigby AS, Andersson B, Lip GYH, van Veldhuisen DJ, Shibata MC, Wedel H, B\u00f6hm M. Effect of age and sex on efficacy and tolerability of \u03b2 blockers in patients with heart failure with reduced ejection fraction: individual patient data meta-analysis. BMJ. 2016;353:i1855.","journal-title":"BMJ"}],"container-title":["Drugs & Aging"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s40266-018-0625-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s40266-018-0625-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,12,10]],"date-time":"2019-12-10T19:10:52Z","timestamp":1576005052000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s40266-018-0625-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,12,11]]},"references-count":62,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,2]]}},"alternative-id":["625"],"URL":"https:\/\/doi.org\/10.1007\/s40266-018-0625-4","relation":{},"ISSN":["1170-229X","1179-1969"],"issn-type":[{"value":"1170-229X","type":"print"},{"value":"1179-1969","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,12,11]]},"assertion":[{"value":"11 December 2018","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"No sources of funding were used in the preparation of this review article.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Joanna Osmanska has no conflicts of interest that are directly relevant to the contents of this article. Pardeep S. Jhund has received speakers\u2019 fees from Novartis, advisory board fees from Novartis, Vifor Pharma, Boehringer Ingelheim and Amgen, and research grants from Boehringer Ingelheim.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}